



Express Mail No. EM180791246US

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/517,741
Filing Date	January 3, 2006
First Named Inventor	John Foekens
Art Unit	1634
Examiner Name	Carla J. Myers
Attorney Docket Number	47675-93

Sheet	1	of	5
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ¹ (if known)			
		US- 5744305	04-28-1998	Fodor et al.	
		US- 5786146	07-28-1998	Herman et al.	
		US- 5837832	11-17-1998	Chee et al.	
		US- 6265171	07-24-2001	Herman et al.	
		US- 6331393	12-18-2001	Laird et al.	
		US- 6596488	07-22-2003	Pfeifer et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		DE 10245779.4	10-01-2002	Epigenomics AG		
		DE 10300096.8	01-07-2003	Epigenomics AG		
		DE 10317955.0	04-17-2003	Epigenomics AG		
		EP 1167975	01-02-2002	Universite Rene Descartes		
		WO 95/00669	01-05-1995	Pharmacia Biotech AB		
		WO 95/15373	06-08-1995	McGill University		
		WO 97/45560	12-04-1997	North Shore University		
		WO 97/46705	12-11-1997	Johns Hopkins University		
		WO 99/28498	06-10-1999	Epigenomics GMBH		
		WO 01/019845	03-22-2001	Johns Hopkins University		
		WO 01/068912	09-20-2001	Epigenomics AG		
		WO 01/081622	11-01-2001	Epigenomics AG		
		WO 02/002806	01-10-2002	Epigenomics AG		
		WO 02/059347	08-01-2002	Johns Hopkins University		
		WO 03/052135	06-26-2003	Epigenomics AG		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/517,741
		Filing Date	January 3, 2006
		First Named Inventor	John Foekens
		Art Unit	1634
		Examiner Name	Carla J. Myers
Sheet	2	of	5
		Attorney Docket Number	47675-93

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BERNS et al., "Predictive value of SRC-1 for taxomifen response of recurrent breast cancer," Breast Cancer Research and Treatment, 1998, pp. 87-92, Volume 48	
		BIECHE et al., "The CGA gene as new predictor of the response to endocrine therapy in ERα-positive menopausal breast cancer patients," Oncogene, 2001, pp. 6955-6959, Volume 20	
		BIECHE et al., "Identification of CGA as a Novel Estrogen Receptor-responsive Gene in Breast Cancer: An Outstanding Candidate Marker to Predict the Response to Endocrine Therapy," Cancer Research, February 15, 2001, pp. 1652-1658, Volume 61	
		BRATTSAND, "Correlation of oncoprotein 18/stathmin expression in human breast cancer with established prognostic factors," British Journal of Cancer, 2000, pp. 311-318, Volume 83, Number 3	
		CHANG et al., "Prediction of Clinical Outcome from Primary Tamoxifen by Expression of Biologic Markers in Breast Cancer Patients," Clinical Cancer Research, February 2000, pp. 616-621, Volume 6	
		CIOCCA et al., "Molecular Markers for Predicting Response to Tamoxifen in Breast Cancer Patients," Endocrine, August 2000, pp. 1-10, Volume 13, No. 1	
		CURMI et al., "Overexpression of stathmin in breast carcinomas points out to highly proliferative tumours," British Journal of Cancer, 2000, pp. 142-150, Volume 82, Number 1	
		DUDOIT et al., "Statistical Methods for Identifying Differentially Expressed Genes in Replicated cDNA Microarray Experiments," Statistica Sinica, 2002, pp. 111-139, Volume 12	
		ELLEDGE et al., "bcl-2, p53, and Response to Tamoxifen in Estrogen Receptor-Positive Metastatic Breast Cancer: A Southwest Oncology Group Study," Journal of Clinical Oncology, May 1997, pp. 1916-1922, Volume 15, No. 5	
		FARCZADI et al., "Changes in apoptosis, mitosis, Her-2, p53 and Bcl2 expression in breast carcinomas after short-term tamoxifen treatment," Neoplasma, 2002, pp. 101-103, Volume 49, No. 2	
		FEIL et al., "Methylation analysis on individual chromosomes: improved protocol for bisulphite genomic sequencing," Nucleic Acids Research, 1994, pp. 695-696, Volume 22, No. 4	
		GITAN et al., "Methylation-Specific Oligonucleotide Microarray: A New Potential for High-Throughput Methylation Analysis," Genome Research, 2001, pp. 158-164, Volume 12	
		GOLDHIRSCH et al., "Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer," Journal of the National Cancer Institute, November 4, 1998, pp. 1601-1608, Volume 90, Number 21	
		GONZALGO et al., "Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE), Nucleic Acids Research, 1997, pp. 2529-2531, Volume 25, No. 12	
		GOUGH et al., "Identification of the primary gene defect at the cytochrome P450 CYP2D locus," Nature, October 25, 1990, pp. 773-776, Volume 347, No. 6295	
		GRIGG et al., "Sequencing 5-Methylcytosine Residues in Genomic DNA," BioEssays, June 1994, pp. 431-436, Volume 16, No. 6	
		GUT et al., "DNA and Matrix Assisted Laser Desorption Ionization Mass Spectrometry," Molecular Biology: Current Innovations and Future Trends, 1995, pp. 147-157, Horizon Scientific Press, Wymondham, United Kingdom	
Examiner Signature			Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Application Number	10/517,741
		Filing Date	January 3, 2006
		First Named Inventor	John Foekens
		Art Unit	1634
		Examiner Name	Carla J. Myers
Sheet	3	of	5
		Attorney Docket Number	47675-93

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GUT et al., "A procedure for selection DNA alkylation and detection by mass spectrometry," Nucleic Acids Research, 1995, pp. 1367-1373, Volume 23, No. 8	
		HARBECK et al., "Clinical Relevance of Invasion Factors Urokinase-Type Plasminogen Activator and Plasminogen Activator Inhibitor Type 1 for Individualized Therapy Decisions in Primary Breast Cancer Is Greatest When Used in Combination," Journal of Clinical Oncology, February 15, 2002, pp. 1000-1007, Volume 20, No. 4	
		HEID et al., "Real Time Quantitative PCR," Genome Research, 1996, pp. 986-994, Volume 6	
		HERMAN et al., "Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands," September 1996, pp. 9821-9826, Volume 93	
		HOUSTON et al., "Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer," British Journal of Cancer, 1999, pp. 1220-1226, Volume 79, No. 7/8	
		HUANG et al., "Methylation profiling of CpG islands in human breast cancer cells," Human Molecular Genetics, 1999, pp. 459-470, Volume 8, Number 3	
		HUBER et al., "Variance stabilization applied to microarray data calibration and to the quantification of differential expression," Bioinformatics, 2002, pp. S96-S104, Volume 18, Supplement 1	
		KANG et al., "Methylation in the p53 Promoter Is a Supplementary Route to Breast Carcinogenesis: Correlation between CpG Methylation in the p53 Promoter and the Mutation of the p53 Gene in the Progression from Ductal Carcinoma In Situ to Invasive Ductal Carcinoma," Laboratory Investigation, 2001, pp. 573-579, Volume 81, No. 4	
		KARAS et al., "Laser Desorption Ionization of Proteins with Molecular Masses Exceeding 10 000 Daltons," Analytical Chemistry, October 15, 1988, pp. 2299-2301, Volume 60, No. 20	
		KIM et al., "Hypermethylation of RASSF1A Promoter Is Associated with the Age at Starting Smoking and a Poor Prognosis in Primary Non-Small Cell Lung Cancer," Cancer Research, July 1, 2003, pp. 3743-3746, Volume 63	
		KUZMIN et al., "Inactivation of RAS Association Domain Family 1A Gene in Cervical Carcinomas and the Role of Human Papillomavirus Infection," Cancer Research, April 15, 2003, pp. 1888-1893, Volume 63	
		LAPIDUS et al., "Methylation of Estrogen and Progesterone Receptor Gene 5' CpG Islands Correlates with Lack of Estrogen and Progesterone Receptor Gene Expression in Breast Tumors," Clinical Cancer Research, May 1996, pp. 805-810, Volume 2	
		LÜCKE et al., "Inhibiting Mutations in the Transforming Growth Factor β Type 2 Receptor in Recurrent Human Breast Cancer," Cancer Research, January 15, 2001, pp. 482-485, Volume 61	
		MARTENS et al., "Epigenetic signature predicts failure of endocrine therapy in patients with recurrent breast cancer," Breast Cancer Research and Treatment, June 3, 2003, p. S72, Volume 82, No. Supp. 1, abstract only	
		MARTIN et al., "Genomic sequencing indicates a correlation between DNA hypomethylation in the 5' region on the pS2 gene and its expression in human breast cancer cell lines," Gene, 1995, pp. 261-264, Volume 157	
		MARTIN et al., "Involvement of DNA Methylation in the Control of the Expression of an Estrogen-Induced Breast-Cancer-Associated Protein (pS2) in Human Breast Cancers," Journal of Cellular Biochemistry, 1997, pp. 95-106, Volume 65	

Examiner Signature		Date	
		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/517,741
				Filing Date	January 3, 2006
				First Named Inventor	John Foekens
				Art Unit	1634
				Examiner Name	Carla J. Myers
Sheet	4	of	5	Attorney Docket Number	47675-93

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MODEL et al., "Statistical process control for large scale microarray experiments," Bioinformatics, 2002, pp. S155-S163, Volume 18, Supplement 1	
		OJALA et al., "mRNA differential display of gene expression in colonic carcinoma," Electrophoresis, June 2002, pp. 1667-1676, Volume 23, No. 11	
		OLEK et al., "A modified and improved method for bisulphite based cytosine methylation analysis," Nucleic Acids Research, 1996, pp. 5064-5066, Volume 24, No. 24	
		OLEK et al., "The pre-implantation ontogeny of the H19 methylation imprint," Nature Genetics, November 1997, pp. 275-276, Volume 17	
		OTTAVIANO et al., "Methylation of the Estrogen Receptor Gene CpG Island Marks Loss of Estrogen Receptor Expression in Human Breast Cancer Cells," Cancer Research, May 15, 1994, pp. 2552-2555, Volume 54	
		PICHON et al., "Clinical significance of the estrogen regulated pS2 protein in mammary tumours," Critical Reviews Oncology/Hematology, August 1993, pp. 13-21, Volume 15, Number 1	
		RAMAN et al., "Compromised H0XA5 function can limit p53 expression in human breast tumors," Nature, June 22, 2000, pp. 974-978, Volume 405	
		REIN et al., "SURVEY and SUMMARY Identifying 5-methylcytosine and related modifications in DNA genomes," Nucleic Acids Research, 1998, pp. 2255-2264, Volume 26, No. 10	
		RODRIGUES et al., "Cytochrome P450 Pharmacogenetics in Drug Development: In Vitro Studies and Clinical Consequences," Current Drug Metabolism, June 2002, pp. 289-309, Volume 3, No. 3	
		SAKAI et al., "Prognostic Significance of β -Microseminoprotein mRNA Expression in Prostate Cancer," The Prostate, March 1, 1999, pp. 278-284, Volume 38, No. 4	
		SANGER et al., "DNA sequencing with chain-terminating inhibitors," PNAS, December 1977, pp. 5463-5467, Volume 74, No. 12	
		UMBRICHT et al., "Hypermethylation of 14-3-3 σ (stratifin) is an early event in breast cancer," Oncogene, 2001, pp. 3348-3353, Volume 20	
		VIRMANI et al., "Hierarchical Clustering of Lung Cancer Cell Lines Using DNA Methylation Markers," Cancer Epidemiology, Biomarkers & Prevention, March 2002, pp. 291-297, Volume 11	
		WATANABE et al., "Isolation of Estrogen-Responsive Genes with a CpG Island Library," Molecular and Cellular Biology, January 1998, pp. 442-449, Volume 18, No. 1	
		XIONG et al., "COBRA: a sensitive and quantitative DNA methylation assay," Nucleic Acids Research, 1997, pp. 2532-2534, Volume 25, No. 12	
		YAN et al., "Dissecting Complex Epigenetic Alterations in Breast Cancer Using CpG Island Microarrays," Cancer Research, December 1, 2001, pp. 8375-8380, Volume 61	
		YU et al., "Specific Inhibition of PCR by Non-Extendable Oligonucleotides Using a 5' to 3' Exonuclease-Deficient DNA Polymerase," BioTechniques, 1997, pp. 714-720, Volume 23, Number 4	

Examiner Signature	Date	Considered
--------------------	------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04 ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known Application Number 10/517,741 Filing Date January 3, 2006 First Named Inventor John Foekens Art Unit 1634 Examiner Name Carla J. Myers Attorney Docket Number 47675-93	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>					
Sheet	5	of	5		

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformation with MPEP 609. Draw line through citation if not in conformation and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional).² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible.⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.